Sessa C, Galeano D, Zanoli L, Delsante M, Rossi G, Morale W
Drugs Context. 2025; 14.
PMID: 40017729
PMC: 11867167.
DOI: 10.7573/dic.2024-9-1.
Wang Y, Lei K, Zhao L, Zhang Y
MedComm (2020). 2024; 5(10):e760.
PMID: 39372389
PMC: 11450256.
DOI: 10.1002/mco2.760.
Yang Y, Zou G, Wei X, Zhang Z, Zhuo L, Xu Q
Front Immunol. 2024; 15:1302909.
PMID: 38846934
PMC: 11153720.
DOI: 10.3389/fimmu.2024.1302909.
Zhang H, Zhang C, Su H
Kidney Med. 2024; 6(5):100816.
PMID: 38720788
PMC: 11077163.
DOI: 10.1016/j.xkme.2024.100816.
Rui M, Jiang L, Pan J, Huang X, Cui J, Zhang S
Int Urol Nephrol. 2024; 56(9):3047-3055.
PMID: 38642210
DOI: 10.1007/s11255-024-04056-y.
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.
Liu F, Ryan S, Fahnoe K, Morgan J, Cheung A, Storek M
Mol Ther. 2024; 32(4):1061-1079.
PMID: 38382529
PMC: 11163200.
DOI: 10.1016/j.ymthe.2024.02.001.
Large B-cell Lymphoma-Associated Membranous Nephropathy With Positive PLA2R on Kidney Biopsy.
Al-Khazraji M, Al-Mufti I, Al-Khazraji Y
Cureus. 2023; 15(11):e48902.
PMID: 38106713
PMC: 10725250.
DOI: 10.7759/cureus.48902.
Identification of biomarkers related to immune and inflammation in membranous nephropathy: comprehensive bioinformatic analysis and validation.
Zhang P, Geng Y, Tang J, Cao Z, Xiang X, Yang K
Front Immunol. 2023; 14:1252347.
PMID: 37876929
PMC: 10590909.
DOI: 10.3389/fimmu.2023.1252347.
Knowledge Translation in Glomerulonephritis: Successes in Translational Research From the Bench to Bedside.
Yau K, Wang C, Al Batran R, MacPhee A, Beaucage M, Farragher J
Can J Kidney Health Dis. 2023; 10:20543581231191839.
PMID: 37637870
PMC: 10457520.
DOI: 10.1177/20543581231191839.
Clinical covariates influencing clinical outcomes in primary membranous nephropathy.
Westermann L, Rottmann F, Hug M, Staudacher D, Wobser R, Arnold F
BMC Nephrol. 2023; 24(1):235.
PMID: 37563703
PMC: 10413503.
DOI: 10.1186/s12882-023-03288-x.
Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis.
Zhong H, Li H, Zhou T, Zhong Z
Arch Med Sci. 2023; 19(2):411-419.
PMID: 37034519
PMC: 10074182.
DOI: 10.5114/aoms.2020.99899.
The Many Faces of NELL1 MN.
Sethi S
Clin Kidney J. 2023; 16(3):442-446.
PMID: 36865014
PMC: 9972807.
DOI: 10.1093/ckj/sfac237.
Integrated Network Pharmacology Analysis and Experimental Validation to Investigate the Molecular Mechanism of Triptolide in the Treatment of Membranous Nephropathy.
Zhang P, Tang J, Yang K, Zheng Q, Dong Z, Geng Y
Drug Des Devel Ther. 2022; 16:4061-4076.
PMID: 36448035
PMC: 9701458.
DOI: 10.2147/DDDT.S386031.
Toxic Occupational Exposures and Membranous Nephropathy.
Cremoni M, Agbekodo S, Teisseyre M, Zorzi K, Brglez V, Benzaken S
Clin J Am Soc Nephrol. 2022; 17(11):1609-1619.
PMID: 36283759
PMC: 9718038.
DOI: 10.2215/CJN.02930322.
Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy.
Miao H, Zhang Y, Yu X, Zou L, Zhao Y
Front Pharmacol. 2022; 13:969930.
PMID: 36176440
PMC: 9513429.
DOI: 10.3389/fphar.2022.969930.
The Alternative Pathway Is Necessary and Sufficient for Complement Activation by Anti-THSD7A Autoantibodies, Which Are Predominantly IgG4 in Membranous Nephropathy.
Manral P, Caza T, Storey A, Beck Jr L, Borza D
Front Immunol. 2022; 13:952235.
PMID: 35874690
PMC: 9301376.
DOI: 10.3389/fimmu.2022.952235.
The Role of Anti-PLAR and Anti-THSD7A Antibodies in the Pathogenesis and Diagnostics of Primary Membranous Nephropathy: A Review of Current Knowledge for Clinical Practice.
Smarz-Widelska I, Chojeta D, Koziol M
Int J Environ Res Public Health. 2022; 19(9).
PMID: 35564696
PMC: 9104191.
DOI: 10.3390/ijerph19095301.
Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy.
Jatem-Escalante E, Martin-Conde M, Gracia-Lavedan E, Benitez I, Gonzalez J, Colas L
Clin Kidney J. 2021; 14(12):2556-2562.
PMID: 34950467
PMC: 8690096.
DOI: 10.1093/ckj/sfab116.
Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis Nrf2/HO-1 Pathway.
Wang X, Liu J, Tian R, Zheng B, Li C, Huang L
Front Pharmacol. 2021; 12:727874.
PMID: 34867334
PMC: 8640486.
DOI: 10.3389/fphar.2021.727874.
Complete Resolution of Paraneoplastic Membranous Nephropathy Following Curative Therapy of Triple-Negative Breast Cancer.
Khan M, Kaur A, Ali A, Boris A, Spitalewitz S
Cureus. 2021; 13(9):e18125.
PMID: 34692335
PMC: 8528167.
DOI: 10.7759/cureus.18125.